Scoop: Novartis’ retreat on CAR-T includes axing most of its senior execs on the team
Novartis’ plan to pull back on CAR-T includes purging most of the senior execs involved in the project, signaling the pharma giant’s R&D retreat is …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
